1. 2011-12-05
  2. MBC’s PI-88 Phase III Hepatocellular Carcinoma Project Awarded Grant Funding of 100 Million...
  1. 2011-11-23
  2. MBC lists on the Taiwan Gretai Securities Market on 23 November 2011.
  1. 2011-11-04
  2. MBC Signed the IPO Fundraising Agreement with the Designated Underwriter
  1. 2011-10-31
  2. MBC Announced Information on the pre-IPO Road show to Institutional Investors
  1. 2011-10-13
  2. MBC’s Chinese Subsidiary Received SFDA Marketing Approval for its Second Generation Nucleic Acid Tes
  1. 2011-10-11
  2. MBC received KFDA approval for Phase III PI-88 Clinical Trial Application
  1. 2011-09-26
  2. MBC Commences PI-88 Hepatocellular Carcinoma Phase III Trial Recruitment
  1. 2011-06-28
  2. PI-88 Receives Orphan Medicinal Product Designation from the European Medicines Agency
  1. 2011-06-23
  2. MBC’s Nucleic Acid Testing platform based instrument awarded tender bid for Chinese Minist...
  1. 2011-06-13
  2. MOEA approved MBC’s PI-88 oncology program is qualified for governmental incentives under Biotech...
  1. 2011-06-03
  2. MBC’s Chinese subsidiary received two SFDA marketing approval for its Nucleic Acid Testing (NAT) kit
  1. 2011-04-19
  2. Progen Licensee Gains Approval for Phase III Clinical Trial
  1. 2010-09-01
  2. MBC submitted to US FDA for Phase 3 clinical trial of PI-88
  1. 2010-06-30
  2. MBC acquired PI-88 global rights to enter into global phase III clinical trial
  1. 2010-04-30
  2. MBC signed a Letter of Intent (LOI) with Progen Pharmaceuticals for PI-88 global developments
  1. 2010-01-11
  2. MBC subsidiary in China received SFDA’s marketing approval for its HBV Nucleic Acid...
  1. 2009-12-25
  2. MBC vaccine development project received funding of approximate US$ 1million from the Ministry of...
  1. 2009-11-18
  2. MBC received PI-88 premium payment of AUD1.8 million from Progen Pharmaceuticals
  1. 2009-11-18
  2. MBC HLA Typing Kits received SBIR subsidy from the Ministry of Economic Affairs (MOEA)
  1. 2009-10-07
  2. MBC and NHRI collaborate in cell-based vaccine technology development
  1. 2009-09-10
  2. MBC signed agreement with NHRI to develop and produce cell-based H1N1 Vaccine
  1. 2009-06-06
  2. MBC HLA typing kits (A/B/C/DR/DQ) received USFDA 510(k)
  1. 2009-02-24
  2. MBC subsidiary in China received SFDA’s marketing approval for its HIV Nucleic Acid...
  1. 2009-01-12
  2. MBC receives ASHI laboratory accreditation for HLA typing, a Taiwan first
  1. 2009-01-01
  2. Medigen Biotechnology Corporation now ASHI laboratory accredited for HLA typing (NEW)
  1. 2008-12-28
  2. Medigen Biotech Holds the “Cross-strait Bilateral Bioproducts Business Symposium”...
  1. 2008-10-27
  2. Medigen Enters Into a Letter of Intent With Pacgen Biotech in Canada
  1. 2008-10-03
  2. Medigen Biotech Received Top Innovation Award by the Ministry of Economic Affairs (MOEA), Taiwan
  1. 2008-03-17
  2. Oncolys BioPharma Ties Up with Medigen Biotech. For Telomelysin
  1. 2008-03-05
  2. Oncolys BioPharma and Medigen Biotechnology Enter Strategic Alliance and Licensing Agreement
  1. 2007-11-28
  2. [Announcment] MBC Collaborates with Academia Sinica for Liver Cancer Development
  1. 2007-10-17
  2. MBC Co-ops with NTU for New Drug Development
  1. 2007-09-03
  2. Tetralogy of Complementary Double-Core Business Model
  1. 2007-08-06
  2. MBC Enters Blood Screening Market in China
  1. 2007-07-09
  2. Taiwanese Bid for Anti-Cancer Drug
  1. 2007-07-02
  2. Big Pharmas Favor BioMed-Industry in Taiwan
  1. 2007-06-16
  2. New Drug PI-88 Decreases Liver Cancer Recurrence to 34%
  1. 2007-06-15
  2. Liver Cancer Treatment Breakthrough by PI-88 Phase II Trial
  1. 2007-04-24
  2. New Drug PI-88 Prevents Liver Cancer Recurrence
  1. 2007-01-17
  2. MBC to Profit from PI-88 Ahead of Time